The PROCTO study is now recruiting patients with moderate ulcerative colitis.
Project summary:The PROCTO trial is a double-blind randomized, placebo-controlled, 24-week, comparative, exploratory phase II proof of concept trial. The trial will be conducted with 2 treatment groups as a parallel group comparison and will serve to compare a 7500 TSO regimen vs. placebo for achieving clinically meaningful responses in ulcerative colitis (UC)
The study is conducted in collaboration between 3 Danish hospitals: Hvidovre Hospital, Herlev Hospital and Bispebjerg Hospital.
Hvidovre Hospital serves as the central site of recruitment to which patient are referred from the two other hospitals.
The study is registered at ClinicalTrial.gov: (no. NCT03565939)
Patients may also directly contact:
Michelle V. Prosberg (MD)
Phone + 45 30343353
Andreas M. Petersen (MD, PhD, principal investigator)